Trial reportAmerican journal of respiratory and critical care medicine2013
Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.
Trial report in American journal of respiratory and critical care medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.The Journal of allergy and clinical immunology · 2019Trial
- Development and Validation of Real-Time Allele-Specific PCR-Based Genotyping of the rs1042713 Variant in the ADRB2 Gene and Its Correlation with Salbutamol Response.Molecular biotechnology · 2026Article
- A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting βPharmacology research & perspectives · 2025Article
- Diagnosis and management of allergy and respiratory disorders in sport: An EAACI task force position paper.Allergy · 2022Article
- Minimal clinically important difference for asthma endpoints: an expert consensus report.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Let research leave you breathless, not physical exercise!ERJ open research · 2018Article
- Tiotropium in asthma: back to the future of anticholinergic treatment.Clinical and molecular allergy : CMA · 2017Review
- Future treatment for asthma.European respiratory review : an official journal of the European Respiratory Society · 2016Article
- IL-13 desensitizes β2-adrenergic receptors in human airway epithelial cells through a 15-lipoxygenase/G protein receptor kinase 2 mechanism.The Journal of allergy and clinical immunology · 2015Article
- Genome-wide association study of short-acting β2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3.American journal of respiratory and critical care medicine · 2015Article
- Exercise and asthma: an overview.European clinical respiratory journal · 2015Article
- Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment.Asthma research and practice · 2015Review
- What the Genetic Background of Individuals with Asthma and Obesity Can Reveal: Is β2-Adrenergic Receptor Gene Polymorphism Important?Pediatric allergy, immunology, and pulmonology · 2014Review
- Update in asthma 2013.American journal of respiratory and critical care medicine · 2014Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
rationaleβ2-Agonists are the treatment of choice for exercise-induced bronchoconstriction (EIB) and act through specific receptors (ADRB2). Arg16Gly polymorphisms have been shown to affect responses to regular use of β2-agonists.
objectivesTo evaluate the influence of the Arg16Gly receptor polymorphism on salmeterol bronchoprotection in EIB and assess predictors of bronchoprotection.
methodsA prospective, genotype-blinded, randomized trial was performed in 26 subjects (12 Arg16Arg and 14 Gly16Gly) with EIB who were not on controller therapy. Subjects were administered salmeterol, 50 μg twice a day for 2 weeks, and underwent an exercise challenge 9 hours after the first and last drug dose. In addition to genotype, FEV1, response to salmeterol, degree of EIB, and exhaled nitric oxide (FE(NO)) at baseline were examined for their association with loss of bronchoprotection (LOB). MEASUREMENTS AND MAIN
resultsThe maximum exercise-induced FEV1 fall was 27.9 ± 1.4% during the run-in period, 8.1 ± 1.2% (70.3 ± 4.1% bronchoprotection) after the first salmeterol dose, and 22.8 ± 3.2% (18.9 ± 11.5% bronchoprotection) after 2 weeks of salmeterol (P = 0.0001). The Arg16Gly polymorphisms were not associated with the LOB in response to salmeterol. FeNO values at baseline were significantly related to the LOB (r = 0.47; P = 0.01). Mean change was a 74 ± 13% LOB in subjects with FE(NO) levels greater than 50 ppb and a 7 ± 16% gain in bronchoprotection in those with FE(NO) levels less than 25 ppb (P = 0.01).
conclusionsThe LOB that occurs with chronic long-acting β2-agonists use is not affected by ADRB2 Arg16Gly polymorphisms. High FE(NO) was associated with marked LOB. Use of long-acting β2-agonists before achieving a reduction in FeNO may need to be avoided. Clinical trial registered with www.clinicaltrials.gov (NCT 00595361).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.